Yes. Thank you. Yes. Thank you. Yes. Thank you very much. Uh, that’s a very, that’s a very important question. Important question. Um, uh, uh, regarding, regarding the monster screen to, um, regarding the monster screen to, uh, I don’t know. Expression profiling, uh, RNA profiling, uh, can expand the excellent precision oncology in three ways, ALK or NTRK or RET...
Yes. Thank you. Yes. Thank you. Yes. Thank you very much. Uh, that’s a very, that’s a very important question. Important question. Um, uh, uh, regarding, regarding the monster screen to, um, regarding the monster screen to, uh, I don’t know. Expression profiling, uh, RNA profiling, uh, can expand the excellent precision oncology in three ways, ALK or NTRK or RET. As you know, some of the driver gene alterations are classified to the fusion variants. And most of these fusion variants work as driver genes. And regarding the RNA sequencing, RNA sequencing can detect in a more sensitive way than the DNA sequencing for the detection of the fusion variants. And second, RNA sequencing can evaluate the RNA expression. So the RNA sequence can detect the overexpression of some target genes, like the target of the antibody drug conjugation, the antibody drug conjugates or the tyrosine kinase inhibitors. And the third, the artificial intelligence feature based on the RNA expression can predict the efficacy of single therapy. So the RNA-based precision oncology can expand the precision oncology regarding the terms of the fusion detection or RNA expression detection or RNA expression-based AI.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
